KRAS G12V /HLA-A*02:01–targeted chimeric antigen receptor T cells exhibit potent preclinical activity against solid tumors
Science Advances · 2026
DOI: 10.1126/sciadv.aea2511 ↗Kurz gefasst
Zurückgezogene Publikation in der Zeitschrift Science Advances, 2026. Verfasst von Huimin Shao und 17 weiteren Autor:innen. Beteiligte Einrichtung: Precision Medicine Centre, The First Affiliated Hospital of Wannan Medical College, Yijishan Hospital, Wuhu 241001, China. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, HLA-A2 Antigen, T-Lymphocytes, Immunotherapy, Adoptive. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Science and Technology Program of Guangdong Province in China, Shenzhen University 2035 Program for Excellent Research, Scientific Major Research Project of Anhui Higher Education Institutions.
Abstract (Originalsprache)
Despite advances in chimeric antigen receptor T cell (CAR T cell) therapy for leukemia and lymphoma, solid tumors remain challenging because of limited target specificity and safety concerns. Neoantigens like KRAS G12V , a highly prevalent yet undruggable mutation in solid tumors, offer tumor-exclusive specificity. This study developed CAR T cells targeting KRAS G12V /HLA-A*02:01 using phage antibody display to identify high-affinity single-chain variable fragments. Engineered B9 CAR T cells specifically lysed tumor cells and patient-derived cancer organoids expressing KRAS G12V /HLA-A*02:01, demonstrating potent antitumor activity. Animal studies showed that B9 CAR T cells effectively controlled tumor growth in subcutaneous pancreatic ductal adenocarcinoma (PDAC) xenografts, as well as in metastatic and peritoneal PDAC models. Safety assessments in NCG-HLA-A2.1 and C57BL/6 mice revealed no detectable in vivo toxicity, supporting the clinical applicability of B9 CAR T cells. Collectively, our neoantigen-targeted CAR T cell therapy against solid tumors shows great potential for future clinical trials in patients with KRAS G12V /HLA-A*02:01, paving the way for clinical translation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Precision Medicine Centre, The First Affiliated Hospital of Wannan Medical College, Yijishan Hospital, Wuhu 241001, China.
- Department of Thyroid Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.
- School of Pharmacy, Wannan Medical College, Wuhu 241002, China.
- Department of Pathology, The First Affiliated Hospital of Wannan Medical College, Yijishan Hospital, Wuhu 241001, China.
- Department of Gastrointestinal Surgery, The First Affiliated Hospital of Wannan Medical College, Yijishan Hospital, Wuhu 241001, China.
- Department of Medical Oncology, The First Affiliated Hospital of Wannan Medical College, Yijishan Hospital, Wuhu 241001, China.
ORCID-Profile: Huimin Shao, Fei Xu, Li Fu, Zhenyu Xu
Förderung
- Science and Technology Program of Guangdong Province in China
- Shenzhen University 2035 Program for Excellent Research
- Scientific Major Research Project of Anhui Higher Education Institutions
- Anhui Provincial Clinical Medicine Research Transformation Special Project
- Key Project of Anhui Province University Outstanding Young Talents Support Fund
- Development of Modern Medical and Pharmaceutical Industry in Anhui Province project
- Outstanding Youth Project of Anhui University natural science
- 2023 Anhui Provincial Health and Health Research Project
Zitieren
APA
Shao, H., Xu, F., Xu, J., Zhou, L., Wu, Y., He, L., Qian, X., He, W., Jiao, N., Xia, Y., Zhao, J., Sheng, L., Mao, G., Ma, T., Wang, W., Luo, S., Fu, L., & Xu, Z. (2026). KRAS G12V /HLA-A*02:01–targeted chimeric antigen receptor T cells exhibit potent preclinical activity against solid tumors. Science Advances. https://doi.org/10.1126/sciadv.aea2511
Vancouver
Shao H, Xu F, Xu J, Zhou L, Wu Y, He L, et al. KRAS G12V /HLA-A*02:01–targeted chimeric antigen receptor T cells exhibit potent preclinical activity against solid tumors. Science Advances. 2026. doi:10.1126/sciadv.aea2511
BibTeX
@article{Shao2026,
author = {Shao, Huimin and Xu, Fei and Xu, Jiangyue and Zhou, Lingjie and Wu, Yao and He, Lianjun and Qian, Xueyi and He, Weijie and Jiao, Nanlin and Xia, Yabin and Zhao, Jun and Sheng, Lili and Mao, Guoliang and Ma, Tao and Wang, Wei and Luo, Shaoxiang and Fu, Li and Xu, Zhenyu},
title = {KRAS G12V /HLA-A*02:01–targeted chimeric antigen receptor T cells exhibit potent preclinical activity against solid tumors},
journal = {Science Advances},
year = {2026},
doi = {10.1126/sciadv.aea2511}
}
EUVIMED